New insights into the mechanisms and management of atrial fibrillation.
Atrial fibrillation (AF) is a common contributor to cardiovascular morbidity and mortality. Two generally acceptable strategies exist for long-term AF management, with ongoing studies comparing the overall mortality associated with each. One strategy aims to maintain sinus rhythm, with antiarrhythmic agents if necessary, thereby preserving physiological cardiac electrical function but exposing the patient to the potential side effects of potent drugs. The second approach is to control the ventricular rate and prevent thromboembolic complications with anticoagulants, leaving the patient with AF. Both beta-blocking agents and calcium antagonists are more effective than digoxin in achieving rate control. Several nonpharmacological therapies including catheter ablation, implantable devices and surgical interventions show promise for rate control and maintenance of sinus rhythm. This paper provides an overview of new developments in pharmacological and nonpharmacological therapy. Key features of recently published clinical guidelines, including a unified classification scheme for AF and issues relating to rate control and maintenance of sinus rhythm, are considered. In addition, preliminary results from the recently presented AFFIRM study, the largest AF trial to date, are summarized. Finally, we discuss recent insights into the basic mechanisms underlying AF that have potentially significant clinical implications.
Khairy
Paul
P
Department of Medicine, Université de Montréal, Montreal, Que.
Nattel
Stanley
S
D000638:Amiodarone / Q000627:therapeutic use; D000889:Anti-Arrhythmia Agents / Q000008:administration & dosage / Q000627:therapeutic use; D000925:Anticoagulants / Q000627:therapeutic use; D001281:Atrial Fibrillation / Q000188:drug therapy* / Q000503:physiopathology*; D006328:Cardiac Catheterization; D006801:Humans; D017410:Practice Guidelines as Topic; D011405:Propafenone / Q000627:therapeutic use; D013015:Sotalol / Q000627:therapeutic use; D014859:Warfarin / Q000627:therapeutic use
D000889:Anti-Arrhythmia Agents; D000925:Anticoagulants; D014859:Warfarin; D011405:Propafenone; D013015:Sotalol; D000638:Amiodarone